Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO January 21, 2025
Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference December 16, 2024
Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation October 9, 2024
Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients August 21, 2024
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards August 16, 2024
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range August 14, 2024
